Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.
Maria-Victoria Mateos-MantecaRobert Z OrlowskiEnrique María OcioPaula Rodríguez-OteroDonna ReecePhillipe MoreauNikhil MunshiDavid E AviganDavid S SiegelRazi GhoriMohammed Z H FarooquiPatricia MarinelloJesús San F MiguelPublished in: British journal of haematology (2019)